Tenet Healthcare (NYSE: THC) director Lynch sells 3,837 common shares

Rhea-AI Filing Summary

Tenet Healthcare Corp director Christopher S. Lynch reported selling 3,837 shares of Common Stock on July 27, 2026, in an open-market or private transaction at $243.44 per share. Following the sale, he directly owns 9,568 shares. The Rule 10b5-1 trading plan checkbox was not marked.

Insider Trade Summary

Net Seller: 3,837 shares

Net Sell 1 txn

Insider Lynch Christopher S.

Role Director

Sold 3,837 shs ($934K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,837	$243.44	$934K

Holdings After Transaction: Common Stock — 9,568 shares (Direct)

Key Figures

Shares Sold: 3837.0000 shares Sale Price per Share: $243.4400 per share Shares Owned After Transaction: 9568.0000 shares

3 metrics

Shares Sold 3837.0000 shares Non-derivative sale of Common Stock on 2026-07-27

Sale Price per Share $243.4400 per share Reported transaction price for the 2026-07-27 sale

Shares Owned After Transaction 9568.0000 shares Total Common Stock directly owned following the sale

Key Terms

non-derivative, open market or private transaction, Rule 10b5-1 trading plan

3 terms

non-derivative financial

"transaction_type: "non-derivative" for the Common Stock sale"

open market or private transaction financial

"transaction_code_description: "Sale in open market or private transaction""

Rule 10b5-1 trading plan regulatory

"The Rule 10b5-1 trading plan checkbox was not marked"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/28/2026 - 08:00 PM Accepted by SEC EDGAR 07/28/2026 - 08:00 PM Learn about SEC filing dates

FAQ

What insider transaction did Tenet Healthcare (THC) report for Christopher S. Lynch?

Tenet Healthcare reported that director Christopher S. Lynch sold 3,837 shares of Common Stock on July 27, 2026. The sale was reported as a non-derivative transaction coded "S," indicating an open-market or private sale of existing shares.

At what price did Christopher S. Lynch sell Tenet Healthcare (THC) shares?

Christopher S. Lynch sold 3,837 shares of Tenet Healthcare Common Stock at an average price of $243.44 per share. This price is reported as a per-share transaction price, reflecting the consideration received for each share sold in the transaction.

How many Tenet Healthcare (THC) shares does Christopher S. Lynch hold after the sale?

After the reported sale, Christopher S. Lynch directly holds 9,568 shares of Tenet Healthcare Common Stock. This post-transaction balance reflects his direct ownership only, as indicated in the filing’s total shares following the transaction field.

Was Christopher S. Lynch’s Tenet Healthcare (THC) trade under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked, indicating the reported sale was not affirmed as made under a Rule 10b5-1 trading plan. No footnotes were provided to describe any separate pre-arranged trading arrangement for this transaction.

What type of security did Christopher S. Lynch trade in this Tenet Healthcare (THC) Form 4?

The transaction involves Common Stock of Tenet Healthcare, reported as a non-derivative security. No options, warrants, or other derivative instruments were included in this Form 4, and the derivative position summary section shows no derivative transactions reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lynch Christopher S.

(Last) (First) (Middle)

14201 DALLAS PARKWAY

(Street)

DALLAS TEXAS 75254

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TENET HEALTHCARE CORP [ THC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		S		3,837	D	$243.44	9,568	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Chad J. Wiener, as Attorney-in-fact for Christopher S. Lynch	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)